Tyrosine Kinase Inhibitors

santa cruz biotechnology, inc.

Log In | Hilfe | Inhaltsübersicht

Willkommen! 0 Produkt(e) im Warenkorb. Bestellen

Antikörper & RNAi
Primärantikörper Sekundärantikörper, Kontroll-IgG und Normalsera Phosphorylierungs-spezifische Antikörper Durchflusszytometrie (FCM) Antikörper für die Immunhistochemie auf Paraffinschnitten Protein A, G PLUS und L-Agarose RNAi Produkte: siRNA, shRNA und shRNA Lentivirale Partikel Gewebeextrakte, Zelllysate und Proteine WB Positivkontrollen - Lysate transfizierter Zellen Kits, Puffer, Substrate, Inhibitoren, Supportprodukte Antikörper für die veterinärmedizinische Forschung
Chemikalien
ChemCruz™ Chemikalien Gebrauchsfertige PBS / TBS Puffer Häufig verwendete Laborchemikalien Farbstoffe Lösungsmittel Substrate für AP und HRP
Laborbedarf
Laborbedarf UltraCruz™ ExactaCruz™ CrystalCruz™
Tiergesundheit
Tiergesundheit Angebote & Aktionen Animal Health News Tiergesundheit Pharmacy UltraCruz Supplements
Highlights
Angebote & Aktionen LIF Protein - für die Zellkultur Antikörper für die veterinärmedizinische Forschung Neue monoklonale Antikörper Neue polyklonale Antikörper New Paraffin Staining
Unternehmen
Unternehmen Kontakt Protokolle Produktreferenzen Datenblatt / SDS Technischer Service Katalog bestellen Chromosomen Index Cruz Credits™ Investigator Award Stellenangebote Distributoren

Home » Supportprodukte » Tyrosine Kinase Inhibitors

Tyrosine Kinase Inhibitors

PRODUKT	CATALOG #	DESCRIPTION	AMOUNT
1,2,3,4,5,6-HEXABROMOCYCLOHEXANE	sc-202398	A potent and specific inhibitor of Jak2 autophosphorylation. Reduces growth hormone-mediated Jak2 autophosphorylation. Does not block autophosphorylation of the epidermal growth factor receptor.	25 mg
3-(3-tert-Butyl-4-methoxybenzylidenyl)indolin-2-one	sc-202410	Selective receptor tyrosine kinase (RTK) inhibitor. Inhibits HER-2 RTK (IC₅₀ ~13µM). Consists predominantly of the E-isomer, contains ~10% of the Z-isomer.	1 mg/5 mg
3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)indolin-2-one	sc-202015	Receptor tyrosine kinase (RTK) inhibitor. Inhibits FLK-1 RTK (IC₅₀~8µM) and EGF RTK. Consists of the E- and Z-isomers.	1 mg/5 mg
3-(4-Hydroxybenzylidenyl)indolin-2-one	sc-202412		1 mg/5 mg
3-(4-Isopropylbenzylidenyl)indolin-2-one	sc-202413	Non-selective inhibitor of receptor tyrosine kinases (RTKs). Inhibits PDGFR, FLK-1, EGFR, HER-2, IGF-1R RTKs (IC₅₀ ~5-25µM) Consists primarily of the E-isomer; contains ~5% of the Z-isomer.	1 mg/5 mg
4-Amino-1-tert-butyl-3-(3-benzyl)pyrazolo[3,4-d]pyrimidine	sc-206804	4-aminopyrazolo[3,4-d]pyridine derivative as a tyrosine kinase inhibitor.	10 mg
ABT-869	sc-359037	Receptor tyrosine kinases (RTKs) mediate critical signaling transduction pathways important for cell survival, growth, and differentiation.	1 mg/5 mg
AG-1288	sc-200664	Tyrosine kinase inhibitor. AG-1288 has been shown to block TNFα-induced cytotoxicity, and to block glucocorticoid-induced COX-2 activity.	10 mg/50 mg
AG-370	sc-205203		1 mg/10 mg
AGL 2043	sc-203808	A cell-permeable, tricyclic quinoxaline compound that acts as a potent, selective, ATP-competitive, and reversible inhibitor of type III receptor tyrosine kinases, PDGFR (IC₅₀ = 800 nM in 3T3 cells; 90 nM against purified PDGFβ-receptor), Flt3, and Kit (IC₅₀ ~1-3 µM). Weakly inhibits PKA, EGFR, IGF-1R, VEGFR, and Src kinases (IC₅₀ > 30 µM). Shown to be non-toxic. Potently inhibits smooth muscle cell proliferation and balloon-induced stenosis in porcine heart.	1 mg
Aminogenistein	sc-207279	An Inhibitor of p56^lck protein-tyrosine kinase activity (IC₅₀ = 1.2uM).	10 mg
Bcr-abl Inhibitor	sc-203836	A cell-permeable pyrimidine compound that binds to the c-abl myristoyl binding pocket. Acts as an allosteric, non-ATP-competitive inhibitor of cellular Bcr-abl activity and Bcr-abl-dependent cellular functions.	5 mg
BML-267	sc-205605	Potent and selective protein tyrosine phosphatase 1B (PTP1B) inhibitor (IC₅₀=11 μM). A similar N-des-methyl analog has been reported and has been used to probe the mechanism of PTP1B-mediated inhibition of leptin signaling. Have limited cell permeability. A cell permeable diethyl ester prodrug of this compound is available.	10 mg/50 mg
Bosutinib	sc-202084	An inhibitor of Src-Abl and Bcr-Abl kinase activity. Shown to block Bcr-Abl activity more potently than Imatinib.	10 mg/25 mg
BPDQ	sc-311299	A cell-permeable, reversible, ATP-competitive, potent and specific inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor.	1 mg
BPIQ-I	sc-202507	Potent and specific inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) (IC₅₀=25 pM).	1 mg
Bruton's Tyrosine Kinase Inhibitor III	sc-311301	A cell-permeable pyrrolopyridinyl-acryloyl compound which acts as a highly potent, selective, and irreversible inhibitor of BTK.	1 mg
Butein	sc-202510	A plant polyphenol which acts as a specific protein tyrosine kinase inhibitor which potently inhibits the EGF receptor.	5 mg
cFMS Receptor Tyrosine Kinase Inhibitor	sc-203877	A cell-permeable diaminopyrimidine compound that inhibits colony-stimulating factor (CSF)-1 resulting in suppression of monocyte growth and bone degradation in vitro and inhibits CSF-1 signaling through cFMS kinase.	1 mg/5 mg
Imatinib mesylate	sc-202180	An inhibitor of the Bcr-Abl tyrosine kinase, suppressing chronic myelogenous leukemia proliferation. Also inhibits tyrosine kinases related to c-Kit and PDGF.	25 mg/100 mg
Daidzein	sc-24001	Daidzein is an inactive analogue of genistein, a tyrosine kinase inhibitor, as well as a phytoestrogen which may play a role in hormone-produced cancers.	100 mg/500 mg
Demethylasterriquinone B1	sc-203025	A cell-permeable insulin mimetic that has been shown to selectively stimulate insulin receptor tyrosine kinase activity without significant effects to IGF-1R, PDGFR, or EGFR.	5 mg
DMPQ dihydrochloride	sc-203927	Potent, selective inhibitor of β-type PDGFR tyrosine kinase. Highly selective over EGFR tyrosine kinase, erbB2, p56, protein kinase A and protein kinase C.	10 mg/50 mg
EGFR Inhibitor	sc-203934	A cell permeable compound that is a highly selective inhibitor of EGFR, via downregulation of antiapoptotic protein survivin.	1 mg
EGFR/ErbB-2 Inhibitor	sc-203935	A cell-permeable 4-anilino quinazoline compound that acts a potent, reversible, and ATP-competitive inhibitors of EGFR and c-erbB2 (IC₅₀ = 20 nM & 79 nM, respectively), members of the type I growth factor receptor family that is involved in breast cancer development and progression. Shown to effectively inhibit the proliferation (IC₅₀ ~ 1.2-2.5 µM) of tumor cells overexpressing EGRF or c-erbB-2.	1 mg
Emodin	sc-202601	Inhibits p56^lck tyrosine kinase. Blocks the growth of v-ras transformed human bronchial epithelial cells. Suppresses HER2/neu tyrosine kinase activity in HER2/neu overexpressing breast cancer cells.	50 mg
FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074	sc-202610	Cell-permeable pyridopyrimidine compound that acts as a potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptors with little effect against EGFR, InsR, MEK, and cPKC.	1 mg
Geldanamycin	sc-200617	A benzoquinone ansamycin which binds specifically to Hsp90 and down-regulates target proteins including tyrosine kinases, steroid receptors, and transcription factors. Also a potent inhbitor of nuclear hormone receptor family.	1 mg/5 mg
Genistein	sc-3515	Highly specific Protein-Tyrosine Kinase (PTK) inhibitor.	100 mg/500 mg
HNMPA	sc-205714	A membrane impermeable inhibitor of insulin receptor tyrosine kinase activity (IC₅₀=100 µM) that was recently shown to inhibit both tyrosine and serine autophosphorylation by the human insulin receptor.	5 mg/25 mg
Hymenialdisine Analogue 1	sc-280808	The indole derivative of Hymenialdisine, a potent inhibitor of a variety of kinases including MEK-1, GSK-3B, and CKI. It also exhibits inhibition of the G2 cell cycle checkpoint at the micromolar concentrations. This compound exhibits very potent	1 mg
JAK Inhibitor I	sc-204021	A Janus activated-kinase and reversible ATP inhibitor. The compound can inhibit Jak1, Jak2, Jak3, Tyk2 , IL2 and IL4 dependent proliferation, and blocks phosphorylation of STAT5	500 µg/1 mg
JAK3 Inhibitor IV	sc-295217	A potent, selective, and ATP-competitive inhibitor of JAK3 (pIC50 = 7.1). A weak inhibitor of JAK1 (pIC50 = 4.4) and EGF-R (pIC50 = 5.6). Undergoes a retro-Michael breakdown to another active analog, 2-naphthylvinyl ketone (JAK3 Inhibitor V) (t½ = 36 min. at 25°C, pH 7.43).	10 mg
JAK3 Inhibitor VI	sc-204022	A cell-permeable 3'-pyridyl oxindole compound that acts as a potent inhibitor of JAK3 at an IC₅₀ of 27 nM.	5 mg
Janex-1	sc-205354	Selectively inhibits the tyrosine kinase activity of JAK3 without affecting the enzymatic activity of JAK1, JAK2, or other protein tyrosine kinases.	1 mg/5 mg
Kojic acid	sc-255228	Tyrosinase inhibitor.	5 g/10 g
Lapatinib Ditosylate	sc-207822	A selective and effective inhibitor of ErbB-2 and EGFR dual tyrosine kinases. Research studies have reported that the compound can inhibit breast cancer cell proliferation.	5 mg
Lck Inhibitor	sc-204052	A cell-permeable, potent, and ATP-competitive inhibitor of Lck.	1 mg
Leflunomide	sc-202209	Immunosuppressive drug that inhibits T and B cell responses in vivo. Inhibitor of tyrosine phosphorylation (tyrosine kinase inhibitor), of dihydroorotate dehydrogenase, an enzyme for de novo pyrimidine synthesis, of TNF-dependent NF-κB activation, and of COX-2. The physiological activity of leflunomide is attributed mainly to its metabolite A77 1726	10 mg/50 mg
N,N-Dimethyl Sunitinib	sc-208065	Sunitinib intermediate that is an angiogenesis inhibitor and antitumor prodrug	1 mg
Nifuroxazide	sc-204128	An inhibitor of STAT activation and signaling. Blocks constitutive phosphorylation of STAT3 by reducing Jak kinase autophosphorylation. Inhibits tyrosine phosphorylation of Jak2 and Tyk2, does not affect EGFR, Src, MAPK or Akt phosphorylation.	500 mg
Nilotinib	sc-202245	An inhibitor of the Bcr-Abl kinase, designed to bind stronger than Imatinib. Effective against both wild type and Imatinib-resistant CML.	10 mg/25 mg
PD 158780	sc-358789	PD 158780 a potent tyrosine kinase inhibitor that can permeate cells and shows no inhibition against FGF or PDGF-mediated tyrosine phosphorylation.	10 mg
PD 158780 solution	sc-202758	A potent tyrosine kinase inhibitor that can permeate cells and shows no inhibition against FGF or PDGF-mediated tyrosine phosphorylation.	500 µg
PD 166285	sc-208153	RTK inhibitor with broad-spectrum properties and displaying anti-angiogenic activity and anti-tumor efficacy when used with PDT (photodynamic therapy).	5 mg
PD 174265	sc-204170	A potent, cell-permeable, reversible, and selective inhibitor of EGF receptor (EGFR) tyrosine kinase activity (IC₅₀ = 450 pM). The reversible nature of this compound makes it a less effective antitumor agent than PD 168393	1 mg
PDGFR Tyrosine Kinase Inhibitor II	sc-204172	A cell-permeable isothiourea compound that specifically, rapidly and reversibly perturbs MreB function without affecting eukaryotic actin polymerization.	1 mg
PDGFR Tyrosine Kinase Inhibitor III	sc-204173	A cell-permeable, potent, selective, and ATP-competitive inhibitor of PDGF receptor family of tyrosine kinases (IC₅₀ = 50 nM for α-PDGFR, 80 nM for β-PDGFR, 50 nM for c-Kit, and 230 nM for Flt3). Inhibits the activities of other kinases only at much higher concentrations (IC₅₀ > 30 µM for EGFR, FGFR, Src, PKA, and PKC). Reported to block PDGF-BB-induced proliferation of porcine aorta smooth muscle cells (IC₅₀ = 250 nM).	1 mg
PDGFR Tyrosine Kinase Inhibitor IV	sc-205794	Indenopyrazole compount that displays potent antiproliferative properties in human tumor cell lines. Acts as a reversible ATP-competitive inhibitor of PDGFR but exhibits less actibity towards Lck, c-Src, and Fyn while exhibiting little to no inhibition toward VEGFR, HER-2, Cdk's-1,-2,-4 &-7, bFGFR-1 and EGFR. Cell-permeable.	1 mg/5 mg
PDGFR Tyrosine Kinase Inhibitor VI, SU6668	sc-204175	A cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs.	5 mg
Pelitinib	sc-208155	A tyrosine kinase inhibitor that is used to prepare formulation for treating primary or secondary cancer.	5 mg
Phenethyl dimethyl caffeate	sc-204841	An Inhibitor of ornithine decarboxylase and protein tyrosine kinase.	50 mg/100 mg
PP 1	sc-203212	A selective and potent Src-family tyrosine kinase inhibitor which binds to the ATP-binding site in tyrosine kinases and Ser/Thr kinases.	1 mg/5 mg
PP 2	sc-202769	An effective and selective inhibitor of Src family kinases. Shown to inhibit Lck, FynT, phosphorylation of FAK and potently inhibits Hck, p56, and p59.	1 mg
Sorafenib	sc-220125	A RAF kinase inhibitor which suppresses ERK phosphorylation.	5 mg/50 mg
Sorafenib Tosylate	sc-357801		100 mg/1 g
Src Kinase Inhibitor I	sc-204303	A potent dual site inhibitior of Src family kinases. Demonstrates strong inhibition of Src (IC₅₀ = 44 nM) and Lck (IC₅₀ = 88 nM), and weaker inhibition of VEGFR2 (IC₅₀ = 0.32 μM) and C-fms (IC₅₀ = 30 μM).	1 mg
Stem-Cell Factor/c-Kit Inhibitor, ISCK03	sc-355981	A cell-permeable, phenyl-imidazolosulfonamide compound that has been shown to inhibit c-ket activity while also blocking SCF-induced c-kit and Erk phosphorylation.	10 mg
SU 16f	sc-204307	A selective platelet derived growth factor receptor β (PDGFRβ) inhibitor with an IC₅₀=10nM.	10 mg/50 mg
SU 6668	sc-204309	ATP-competitive PDGFR, VEGF and FGFR inhibitor. Shows antiangiogenic, anti-inflammatory, antimetastatic and proapototic activity and is orally active.	10 mg/50 mg
Sunitinib Malate	sc-220177	An antineoplastic, multi-kinase inhibitor whichg targets several receptor tyrosine kinases (RTK).	10 mg/100 mg
Syk Inhibitor II	sc-281683	A pyrimidine-carboxamide compound that has been reported to behave as a strong ATP-competitive inhibitor of Syk, with little effect on PKCε, PKCbII, ZAP-70, Btk, and Itk	1 mg
Tandutinib	sc-202353	Piperazinyl quinazoline receptor tyrosine kinase inhibitor. Antineoplastic. Inhibits FLT3 (FMS-Like Tyrosine kinase-3) and c-KIT and PDGF receptor tyrosine kinases.	1 mg/5 mg
trans-1-(3’-Carboxy-4’-hydroxyphenyl)-2-(2,5-dihydroxyphenyl)ethene	sc-208455	This compound is a novel tyrosine kinase inhibitor that shows extremely high potency against immunoprecipitated p56^lck (IC₅₀ = 60nM).	2.5 mg
Tyrphostin 47	sc-216031	An inhibitor of EGFR tyrosine kinase.	5 mg
Tyrphostin A1	sc-3559	Tyrphostin A1 is the inactive form Tyrphostin and is commonly used as a negative control for other Tyrphostins.	25 mg/100 mg
Tyrphostin A23	sc-3554	Belongs to a novel class of low molecular weight proteins that inhibit protein tyrosine kinase and block the EGF-dependent autophosphorylation of the receptor.	10 mg
Tyrphostin A25	sc-3555	A cell-permeable, competitive and reversible inhibitor of substrate binding on protein tyrosine kinases.	25 mg
Tyrphostin AG 30	sc-202042	A potent protein tyrosine kinase inhibitor specific for c-ErbB which results in inhibition of the activation of STAT5 in primary erythroblasts.	5 mg/10 mg
Tyrphostin AG 1295	sc-3558	Selective inhibitor of platelet-derived growth factor receptor protein tyrosine kinase (PDGF-R-PTK) and PDGF-dependent DNA synthesis.	5 mg
Tyrphostin AG 490	sc-216033	Inhibits Jak-2 protein tyrosine kinase (PTK) and interleukin 2 (IL-2) driven mitogenesis. Also triggers apoptosis of tumor cells in Sezary syndrome, which is a leukemic variant of cutaneous T cell lymphoma.	5 mg/25 mg
Tyrphostin AG 528	sc-216034	An inhibitor of EGFR protein tyrosine kinase.	5 mg
Tyrphostin AG 879	sc-3557	A protein tyrosine kinase inhibitor with potential anti-cancer properties.	5 mg/25 mg
Tyrphostin AG 957	sc-204359	A potent tyrosine kinase inhibitor; selectively blocks the tyrosine kinase activity of human p210bcr-abl.	1 mg/5 mg
VEGFR Tyrosine Kinase Inhibitor II	sc-204378	A pyridinyl-anthranilamide compound that displays both antiangiogenic and antitumor properties. Shown to potently inhibit the kinase activities of KDR, Flt-1 and c-Kit (IC₅₀ = 20 nM, 180 nM and 240 nM, respectively), and minimally inhibit c-Src and EGF-R activities (IC₅₀ = 7 µM and 7.3 µM). Further, inactive towards the inhibition of CDK-1, c-Met, IGF-1R and PKA (IC₅₀ > 10 µM).	5 mg
VEGFR Tyrosine Kinase Inhibitor III, KRN633	sc-204379	A cell-permeable, ATP-competitive, reversible inhibitor of VEGFR kinase activity, that has been shown to also inhibit PDGFR-α at higher concentrations.	1 mg
VEGFR Tyrosine Kinase Inhibitor IV	sc-356189	This product is a cell-permeable quinoline-urea compound reported to potently inhibit the kinase activity of VEGFR, EphB2, PDGFR-α, PDGFR-β, c-Kit, and Tie-2.	500 μg
VEGFR Tyrosine Kinase Inhibitor V	sc-356190	This product is a ATP-binding pocket-targeting, cell-permeable, N-cyclopropylnaphthamide compound reported to act as a potent inhibitor against VEGFR1/2/3, c-FMS, RET, Lyn, and c-KIt. This compound is also reported to exhibit reduced activity against 36 other commonly studied kinases.	5 mg
VEGFR2 Kinase Inhibitor I	sc-202850	Highly selective, cell-permeable indolin-2-one class of receptor tyrosine kinase (RTK) inhibitor for murine VEGF-R2. The inhibition is suggested to be competitive with respect to ATP.	1 mg
VEGFR2 Kinase Inhibitor II	sc-204380	Membrane permeant indolin-2-one class of receptor tyrosine kinase (RTK) inhibitor [IC₅₀ = 70 nM for VEGF-R2 (KDR/Flk-1), 920 nM for PDGF-Rβ, 4.92 µM for p60c-src, and 13.3 µM for FGF-R1]. Inhibition is suggested to be competitive with respect to ATP. Although, does not inhibit EGF-R kinase activity (IC₅₀ > 100 µM).	1 mg
VEGFR2 Kinase Inhibitor III	sc-202851	A cell-permeable ATP-competitive inhibitor of VEGFR2, a KDR (kinase insert domain receptor), which is the major growth factor for vascular endothelial cells.	5 mg
VEGFR2 Kinase Inhibitor IV	sc-204381	A potent, ATP-competitive inhibitor of VEGFR-2. Displays ~2-fold greater selectivity for VEGFR-2 over PDGFRb and 10-fold greater selectivity over VEGFR-1 (Flt-1) and VEGFR-3 tyrosine kinase activity.	1 mg
WHI-P 154	sc-204395	JAK3 inhibitor (IC₅₀= 1.8 μM) that displays no activity at JAK1 or JAK2. Inhibits STAT1 activation, iNOS expression and NO production in macrophages in vitro. Induces apoptosis in human glioblastoma cell lines (IC5₅₀ = 158 μM). Inhibits other common kinases including EGFR (IC₅₀50 = 4 nM), Src, Abl, VEGFR, MAPK and PI 3-K.	10 mg/50 mg